A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 x 10(7) pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
Kelleher
Anthony D
AD
Puls
Rebekah L
RL
Bebbington
Mark
M
Boyle
David
D
Ffrench
Rosemary
R
Kent
Stephen J
SJ
Kippax
Sue
S
Purcell
Damian F J
DF
Thomson
Scott
S
Wand
Handan
H
Cooper
David A
DA
Emery
Sean
S
D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005587:Fowlpox virus / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000009:adverse effects / Q000276:immunology
D016915:AIDS Vaccines; D019444:Vaccines, DNA; D007371:Interferon-gamma